Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Falls Church, Virginia Clinical Trials

A listing of Falls Church, Virginia clinical trials actively recruiting patient volunteers.

RESULTS

Found (197) clinical trials

Nilotinib in Huntington's Disease

The investigators performed an open label phase I clinical trial using two commercially available doses of Nilotinib (150 and 300mg capsules) in patients with advanced PDD and DLB. These indications have some overlapping pathologies and clinical symptoms and share common plasma and CSF biomarkers, including alpha-Synuclein, Abeta42/40, total Tau and ...

Phase

5.66 miles

Learn More »

Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease

The study is designed as a multi-site, prospective, 15-month longitudinal, cohort study measuring CSF mHTT in participants with early manifest Stage I or Stage II Huntington's disease (HD).

Phase

5.66 miles

Learn More »

The relatively restricted C4.4a expression pattern provides a target for the selective delivery of a cytotoxic drug to C4.4.a-expressing tumor cells by means of a suitable antibody-drug conjugate. The subject population eligible for the current study will be those subjects with advanced malignancies known to express C4.4a, which are refractory ...

Phase

5.7 miles

Learn More »

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab in Subjects With Advanced GI Tumors (Keynote 596)

The purpose of the Dose Escalation Phase is to examine the safety and determine the maximum tolerated dose of CGX1321 when administered to subjects with advanced solid tumors. The purpose of the Dose Expansion Phase, Roll-over Cohort and Phase 1b is to continue to examine the safety and confirm the ...

Phase

5.7 miles

Learn More »

Experimental Infection of Hookworm-na ve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae

Open-label, dose-escalation clinical study in healthy, hookworm-nave adults: Study site: George Washington Medical Faculty Associates, Washington, DC Number of participants: up to 30 in 3 cohorts of 10 volunteers each In Cohort 1, ten (10) volunteers will receive an inoculum of 25 infectious Necator americanus larvae. In Cohort 2, ten ...

Phase

6.64 miles

Learn More »

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With No Curative First-Line Treatment Option Recurrent or Refractory Solid Tumors And Primary Cns Tumors With or Without Trk Ros1 or Alk Fusions

This is a 5-part, open-label, Phase 1/2 multicenter, dose escalation study in pediatric patients with relapsed refractory solid tumors; 2) primary CNS tumors; 3) neuroblastoma; 4) non-neuroblastoma, extracranial solid tumors with NTRK1/2/3, ROS1 or ALK gene rearrangements; and 5) patients who are otherwise eligible but unable to swallow capsules. The ...

Phase

6.64 miles

Learn More »

A Phase I Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine Adjuvanted

This is a phase 1 first-in-human clinical trial to assess the safety, tolerability, and immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted, in up to 48 healthy adult HIV-negative volunteers. The study is a randomized, double-blind, placebo-controlled dosage-escalation Phase 1 study intended to evaluate the safety and immunogenicity of eOD-GT8 60mer Vaccine, ...

Phase

6.64 miles

Learn More »

Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study

Malignant gliomas are the most common type of brain tumor in adults. They are the second leading cause of cancer mortality in people under the age of 35 and the fourth leading cause in those under the age of 54. Standard therapy for glioblastoma multiforme (GBM) includes surgery followed by ...

Phase

7.35 miles

Learn More »

The purpose of this study is to evaluate the safety and tolerability of INCB050465 when combined with bendamustine and obinutuzumab in relapsed or refractory follicular lymphoma (FL).

Phase

7.35 miles

Learn More »

Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma

A multicenter, non-randomized, open-label, dose-exploration study evaluating two new formulations of oprozomib plus pomalidomide and dexamethasone in patients with relapsed refractory multiple myeloma. The study will be conducted in two parts. Part 1 will evaluate the formulations of oprozomib in combination with dexamethasone only. Part 2 will evaluate the formulations ...

Phase

7.35 miles

Learn More »